Clinical Trial Update: A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II dose-finding study assessing [177Lu]Lu-NeoB in combination with capecitabine for GRPR+, ER+, HER2-negative metastatic breast cancer after progressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• [177Lu]Lu-NeoB

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING